{"id":"https://openalex.org/W2108753267","doi":"https://doi.org/10.1007/s00280-013-2287-6","title":"Investigation into CYP3A4-mediated drug\u2013drug interactions on midostaurin in healthy volunteers","display_name":"Investigation into CYP3A4-mediated drug\u2013drug interactions on midostaurin in healthy volunteers","alternate_titles":[],"publication_year":2013,"publication_date":"2013-10-02","ids":{"openalex":"https://openalex.org/W2108753267","doi":"https://doi.org/10.1007/s00280-013-2287-6","mag":"2108753267","pmid":"https://pubmed.ncbi.nlm.nih.gov/24085261","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/3834177"},"language":"en","primary_location":{"id":"doi:10.1007/s00280-013-2287-6","doi":"https://doi.org/10.1007/s00280-013-2287-6","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00280-013-2287-6","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00280-013-2287-6.pdf","source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2108753267"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s00280-013-2287-6.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5026261845","display_name":"Catherine Dutreix","orcid":"https://orcid.org/0009-0000-0851-3423","observed_orcids":["https://orcid.org/0009-0000-0851-3423"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Catherine Dutreix","raw_affiliation_strings":["Novartis Oncology, Basel, Switzerland, catherine.dutreix@novartis.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Oncology, Basel, Switzerland, catherine.dutreix@novartis.com","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060667293","display_name":"Florence Munarini","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Florence Munarini","raw_affiliation_strings":["Novartis Oncology, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Oncology, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073762461","display_name":"Sebastien Lorenzo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sebastien Lorenzo","raw_affiliation_strings":["Novartis Oncology, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Oncology, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110827406","display_name":"Johannes L. Roesel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Johannes Roesel","raw_affiliation_strings":["Novartis Oncology, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Oncology, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5100645706","display_name":"Yanfeng Wang","orcid":"https://orcid.org/0000-0002-3859-0937","observed_orcids":["https://orcid.org/0000-0002-3859-0937"]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Yanfeng Wang","raw_affiliation_strings":["Novartis Oncology, East Hanover, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Oncology, East Hanover, NJ, USA","institution_ids":["https://openalex.org/I4210117619"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5026261845"],"corresponding_institution_ids":["https://openalex.org/I1283582996"],"apc_list":{"value":4390,"currency":"USD","value_usd":4390},"apc_paid":{"value":4390,"currency":"USD","value_usd":4390},"fwci":1.9594,"has_fulltext":true,"cited_by_count":94,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.82940612,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":99},"biblio":{"volume":"72","issue":"6","first_page":"1223","last_page":"1234"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/midostaurin","display_name":"midostaurin","score":1.0},{"id":"https://openalex.org/keywords/cyp3a4","display_name":"CYP3A4","score":0.9409999847412109},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.9980000257492065},{"id":"https://openalex.org/keywords/ketoconazole","display_name":"ketoconazole","score":0.9570000171661377},{"id":"https://openalex.org/keywords/rifampicin","display_name":"rifampicin","score":1.0},{"id":"https://openalex.org/keywords/midazolam","display_name":"midazolam","score":0.8970000147819519},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7369999885559082},{"id":"https://openalex.org/keywords/enzyme-inhibition","display_name":"enzyme inhibition","score":0.7020000219345093},{"id":"https://openalex.org/keywords/enzyme-induction","display_name":"enzyme induction","score":0.9800000190734863},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.7979999780654907},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.7979999780654907},{"id":"https://openalex.org/keywords/systemic-mastocytosis","display_name":"systemic mastocytosis","score":0.9739999771118164}],"concepts":[{"id":"https://openalex.org/C2776481607","wikidata":"https://www.wikidata.org/wiki/Q6842945","display_name":"Midostaurin","level":3,"score":0.9672362208366394},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.7595071792602539},{"id":"https://openalex.org/C109650736","wikidata":"https://www.wikidata.org/wiki/Q424440","display_name":"CYP3A4","level":4,"score":0.6623024344444275},{"id":"https://openalex.org/C2781064554","wikidata":"https://www.wikidata.org/wiki/Q407883","display_name":"Ketoconazole","level":3,"score":0.5614050030708313},{"id":"https://openalex.org/C97320921","wikidata":"https://www.wikidata.org/wiki/Q718753","display_name":"Drug interaction","level":3,"score":0.49118420481681824},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4499571621417999},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4169401526451111},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.32905077934265137},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.32503873109817505},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.20333802700042725},{"id":"https://openalex.org/C526171541","wikidata":"https://www.wikidata.org/wiki/Q407693","display_name":"Cytochrome P450","level":3,"score":0.15156292915344238},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.10249307751655579},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.09633168578147888},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.0},{"id":"https://openalex.org/C2779548794","wikidata":"https://www.wikidata.org/wiki/Q578726","display_name":"Antifungal","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D002853","descriptor_name":"Chromatography, Liquid","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004790","descriptor_name":"Enzyme Induction","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007654","descriptor_name":"Ketoconazole","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008874","descriptor_name":"Midazolam","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012293","descriptor_name":"Rifampin","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D019311","descriptor_name":"Staurosporine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D019311","descriptor_name":"Staurosporine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D019311","descriptor_name":"Staurosporine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D019311","descriptor_name":"Staurosporine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D051544","descriptor_name":"Cytochrome P-450 CYP3A","qualifier_ui":"Q000096","qualifier_name":"biosynthesis","is_major_topic":false},{"descriptor_ui":"D051544","descriptor_name":"Cytochrome P-450 CYP3A","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D053719","descriptor_name":"Tandem Mass Spectrometry","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D065692","descriptor_name":"Cytochrome P-450 CYP3A Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1007/s00280-013-2287-6","doi":"https://doi.org/10.1007/s00280-013-2287-6","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00280-013-2287-6","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00280-013-2287-6.pdf","source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:2826171","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3834177","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:3834177","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3834177/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemother Pharmacol","raw_type":"Text"},{"id":"pmid:24085261","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24085261","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer chemotherapy and pharmacology","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":{"id":"doi:10.1007/s00280-013-2287-6","doi":"https://doi.org/10.1007/s00280-013-2287-6","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00280-013-2287-6","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00280-013-2287-6.pdf","source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9763000011444092,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320310388","display_name":"Novartis Pharmaceuticals Corporation","ror":"https://ror.org/028fhxy95"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2108753267.pdf","grobid_xml":"https://content.openalex.org/works/W2108753267.grobid-xml"},"referenced_works_count":23,"referenced_works":["https://openalex.org/W1255933066","https://openalex.org/W1970069168","https://openalex.org/W1974630669","https://openalex.org/W1993300766","https://openalex.org/W1998736820","https://openalex.org/W2007044832","https://openalex.org/W2007266721","https://openalex.org/W2009816863","https://openalex.org/W2022108422","https://openalex.org/W2084855648","https://openalex.org/W2103827225","https://openalex.org/W2109331088","https://openalex.org/W2121216306","https://openalex.org/W2123282873","https://openalex.org/W2151222524","https://openalex.org/W2152964734","https://openalex.org/W2154625299","https://openalex.org/W2463908206","https://openalex.org/W2486833119","https://openalex.org/W2513946787","https://openalex.org/W2891756647","https://openalex.org/W2980118725","https://openalex.org/W3202912068"],"related_works":["https://openalex.org/W4391230295","https://openalex.org/W2767526713","https://openalex.org/W4401397596","https://openalex.org/W4283448772","https://openalex.org/W2906842116","https://openalex.org/W2966283333","https://openalex.org/W1875167981","https://openalex.org/W4321178404","https://openalex.org/W4406378436","https://openalex.org/W4365442969"],"abstract_inverted_index":{"PURPOSE:":[0],"Midostaurin":[1,191,232],"(PKC412),":[2],"a":[3,68,84,112,124,159,228],"multitargeted":[4],"tyrosine":[5,11],"kinase":[6,12],"inhibitor":[7,86],"that":[8,35,46,225],"targets":[9],"FMS-related":[10],"3":[13],"and":[14,27,45,108,118,129,148,154,178,214,222],"KIT,":[15],"is":[16,37,227],"in":[17,77,241],"clinical":[18,58],"trials":[19],"for":[20,23,91,101],"the":[21,51,57,81,119,196],"treatment":[22],"acute":[24],"myeloid":[25],"leukemia":[26],"advanced":[28],"systemic":[29],"mastocytosis.":[30],"In":[31],"vitro":[32],"studies":[33,76],"showed":[34],"midostaurin":[36,47,65,107,117,122,147,173,185,213,226],"predominantly":[38],"metabolized":[39],"by":[40,170,182,187,220],"cytochrome":[41],"P450":[42],"3A4":[43],"(CYP3A4)":[44],"inhibits":[48],"and/or":[49],"induces":[50],"same":[52],"enzyme.":[53],"Here,":[54],"we":[55],"address":[56],"relevance":[59],"of":[60,83,106,116,121,146,168,180,198,212],"CYP3A4-related":[61],"drug-drug":[62],"interactions":[63],"with":[64],"as":[66,123],"either":[67],"\"victim\"":[69],"or":[70,94,200,206,238],"\"perpetrator.\"":[71],"METHODS:":[72],"Three":[73],"phase":[74],"I":[75],"healthy":[78],"volunteers":[79],"evaluated":[80],"effects":[82,120],"CYP3A4":[85,95,140,169,181,230,240],"(ketoconazole":[87],"400":[88],"mg":[89,99,133],"daily":[90,100],"10":[92],"days)":[93,103],"inducer":[96],"(rifampicin":[97],"600":[98],"14":[102],"on":[104,136],"concentrations":[105,145,197],"its":[109,149,201,215],"metabolites":[110,216],"following":[111],"single":[113,125,205],"50-mg":[114],"dose":[115,126],"(100":[127],"mg)":[128],"multiple":[130,207],"doses":[131],"(50":[132],"twice":[134],"daily)":[135],"midazolam":[137,199],"(a":[138],"sensitive":[139,160,229],"probe)":[141],"concentration.":[142],"The":[143,210],"plasma":[144],"2":[150],"active":[151],"metabolites,":[152],"CGP62221":[153],"CGP52421,":[155],"were":[156],"determined":[157],"using":[158],"liquid":[161],"chromatography/tandem":[162],"mass":[163],"spectrometry":[164],"method.":[165],"RESULTS:":[166],"Inhibition":[167],"ketoconazole":[171,221],"increased":[172],"exposure":[174,186],"more":[175,188],"than":[176,189],"tenfold,":[177],"induction":[179],"rifampicin":[183],"decreased":[184],"tenfold.":[190],"did":[192,233],"not":[193,234],"appreciably":[194],"affect":[195],"metabolite,":[202],"1'-hydroxymidazolam,":[203],"at":[204],"doses.":[208],"CONCLUSION:":[209],"pharmacokinetics":[211],"was":[217],"affected":[218],"substantially":[219],"rifampicin,":[223],"suggesting":[224],"substrate.":[231],"appear":[235],"to":[236],"inhibit":[237],"induce":[239],"vivo.":[242]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2108753267","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":7},{"year":2024,"cited_by_count":10},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":8},{"year":2020,"cited_by_count":14},{"year":2019,"cited_by_count":11},{"year":2018,"cited_by_count":8},{"year":2017,"cited_by_count":11},{"year":2016,"cited_by_count":8},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":1}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
